-
June 13, 2013
NICE has endorsed GSK's bleeding drug Revolade for use on the NHS.
Full story
-
June 04, 2013
The National Institute for Health and Care Excellence has published draft guidance which it hopes will help improve the diagnosis of serious bowel conditions.
Full story
-
May 31, 2013
Final draft guidance from NICE says yes to Bayer’s Eylea as it looks to be the first licensed drug to compete with Novartis’s Lucentis
Full story
-
May 30, 2013
NICE has issued a Final Appraisal Determination (FAD) backing the use of Bristol-Myers Squibb/AstraZeneca's first-in-class type 2 diabetes treatment Forxiga (dapagliflozin).
Full story
-
May 30, 2013
A study of five European Union (EU) nations finds that Germany provides the most favourable environment for biosimilar drugs, while Italy is the least favourable.
Full story
-
May 28, 2013
NICE final guidance recommends Novartis' Lucentis for macular oedema.
Full story
-
May 22, 2013
Arrangements need to be put in place to ensure that NICE can access all the evidence underlying product licensing decisions taken by the MHRA and t EMA, says the National Audit Office (NAO).
Full story
-
May 22, 2013
The Institute says the drug’s costs are too high and its benefits too uncertain; Roche says patients in England must now rely on Cancer Drugs Fund
Full story
-
May 20, 2013
Former chairman of NICE under scrutiny for surprising move that re-opens debate on the division between pharma and independent regulators
Full story
-
May 17, 2013
Betmiga gets final draft yes from the Institute as Astellas looks to replace its ageing OAB drug Vesicare
Full story